Metformin (off-label for healthspan / metabolic optimisation)

Metformin has genuine human outcome evidence, but for diabetes, not for longevity. Australian Prescriber describes it as "the only glucose-lowering oral drug that has been shown to reduce mortality in patients with diabetes" (https://australianprescriber.tg.org.au/articles/safe-prescribing-of-metformin-in-diabetes.html). That finding is in people with type 2 diabetes and is a diabetes-treatment result, not evidence of an anti-ageing effect in healthy people. For healthspan specifically, the evidence base is animal and mechanistic plus observational, with no completed randomised trial reporting a longevity or healthspan endpoint. The TAME trial (Targeting Aging with Metformin), the study designed to test exactly this question, has NOT reported: as of 2026 no efficacy results have been published, and primary outcomes are not expected before 2027 to 2028 (https://www.stackingyears.com/blog/tame-trial-metformin-2026-status-update). Note for the record that at least one low-quality source (imedic.health) circulates a claim that TAME has reported positive results; that claim is contradicted by better sourcing and should not be repeated. Rodent lifespan data are inconsistent and strain-dependent, and a recognised counter-signal exists in humans: metformin blunts the adaptation response to exercise training, which is a plausible healthspan negative in an otherwise healthy user. Vively's own consumer content concedes the drug "is not approved in Australia or the United States specifically for weight loss" and that any off-label prescribing "must be based on individual clinical assessment" (https://www.vively.com.au/post/can-you-use-metformin-for-weight-loss). Bottom line: well-characterised, cheap, and safe enough at the population level, but the healthspan proposition remains unproven in humans.

What it is

Plain-language explainer

Categories